Literature DB >> 31189088

Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy.

Jack Dalla Via1, Robin M Daly2, Patrick J Owen2, Niamh L Mundell2, Timo Rantalainen3, Steve F Fraser2.   

Abstract

Androgen deprivation therapy (ADT) improves survival in men with advanced prostate cancer (PCa), but has been associated with compromised skeletal health and increased fracture risk. However, limited previous research has investigated determinants of bone strength beyond DXA-derived areal bone mineral density (aBMD) in this population group. The aim of this cross-sectional study was to investigate the effects of ADT in men with PCa on BMD, bone structure, estimates of whole bone strength and cortical bone distribution. A total of 70 ADT-treated men, 52 PCa controls and 70 healthy controls had DXA lumbar spine and proximal femur aBMD and pQCT distal (4%) and proximal (66%) tibia and radius cortical and trabecular volumetric BMD (vBMD), bone structure, strength and cortical bone distribution assessed. Analyses included BMI and/or tibia/radius length as covariates. On average, ADT-treated men had a higher BMI than PCa (P < 0.05) but not healthy controls. ADT-treated men had 7.2-7.8% lower lumbar spine aBMD than PCa (P = 0.037) and healthy controls (P = 0.010), with a trend for a lower total hip aBMD in the ADT-treated men (P = 0.07). At the distal tibia, total bone area was 6.2-7.3% greater in ADT-treated men than both controls (P < 0.01), but total vBMD was 8.4-8.7% lower in ADT-treated men than both controls (P < 0.01). Moreover, bone strength index (BSI) was 10.8% lower relative to healthy controls only (P < 0.05). At the distal radius, ADT-treated men had lower total and trabecular vBMD (10.7-14.8%, P < 0.05) and BSI (23.6-27.5%, P < 0.001) compared to both controls. There were no other differences in bone outcomes at the proximal tibia or radius. In conclusion, ADT treatment for PCa was associated with lower BMD and estimated compressive bone strength, particularly at trabecular skeletal sites (lumbar spine, and distal tibia and radius), compared to controls, but there were no consistent differences in cortical bone structure, distribution or bending strength.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Androgen deprivation therapy; Bone distribution; Bone mineral density; Bone strength; Prostate Cancer

Mesh:

Substances:

Year:  2019        PMID: 31189088     DOI: 10.1016/j.bone.2019.06.005

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  3 in total

1.  Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.

Authors:  Janet E Brown; Catherine Handforth; Juliet E Compston; William Cross; Nigel Parr; Peter Selby; Steven Wood; Lawrence Drudge-Coates; Jennifer S Walsh; Caroline Mitchell; Fiona J Collinson; Robert E Coleman; Nicholas James; Roger Francis; David M Reid; Eugene McCloskey
Journal:  J Bone Oncol       Date:  2020-08-02       Impact factor: 4.072

2.  Androgen Deprivation Therapy Differentially Impacts Bone and Muscle in the Short Term in Physically Active Men With Prostate Cancer.

Authors:  Naim M Maalouf; Avneesh Chhabra; Jason Zafereo; Ross Querry; Dwight A Towler; Uma J Thakur; Joseph Frankl; John R Poindexter; Bayan Mogharrabi; May Xac; Orhan K Öz; Craig D Rubin
Journal:  JBMR Plus       Date:  2021-11-15

3.  TERF1 downregulation promotes the migration and invasion of the PC3 prostate cancer cell line as a target of miR‑155.

Authors:  Wei Chen; Li-Na He; Yong Liang; Xiang Zeng; Cui-Ping Wu; Ming-Qiang Su; Yang Cheng; Jian-Hui Liu
Journal:  Mol Med Rep       Date:  2020-10-21       Impact factor: 2.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.